We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

54 hedge funds and large institutions have $4.75M invested in Navidea Biopharmaceuticals Inc. in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

0% more funds holding

Funds holding: 54 → 54 (0)

4% less capital invested

Capital invested by funds: $4.93M → $4.75M (-$180K)

15% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 13

Holders
54
Holders Change
–
Holders Change %
0%
% of All Funds
1.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
11
Reduced
13
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$23.3K
2
Citigroup
Citigroup
New York
+$14.9K
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$14.5K
4
PP
PDS Planning
Ohio
+$13.4K
5
USAA
United Services Automobile Association
Texas
+$9.83K

Top Sellers

Rank Fund Capital Flow
1
SFS
Sowell Financial Services
Arkansas
-$76K
2
UBS Group
UBS Group
Switzerland
-$33.1K
3
Jane Street
Jane Street
New York
-$24.6K
4
HighTower Advisors
HighTower Advisors
Illinois
-$23.7K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$10.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.85M -$10.6K -1,420 -0.5%
BlackRock
2
BlackRock
New York
$891K -$5.83K -779 -0.6%
HIIFS
3
Harel Insurance Investments & Financial Services
Israel
$281K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$259K – – –
BCM
5
Bridgeway Capital Management
Texas
$234K – – –
Jacobs Levy Equity Management
6
Jacobs Levy Equity Management
New Jersey
$157K – – –
California Public Employees Retirement System
7
California Public Employees Retirement System
California
$132K – – –
Northern Trust
8
Northern Trust
Illinois
$88K – – –
SFS
9
Sowell Financial Services
Arkansas
$82K -$76K -10,157 -40%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$72K +$14.5K +1,933 +24%
WS
11
Wedbush Securities
California
$70K +$9.35K +1,250 +15%
Wells Fargo
12
Wells Fargo
California
$65K -$5.2K -695 -7%
Citadel Advisors
13
Citadel Advisors
Florida
$63K +$23.3K +3,117 +55%
Morgan Stanley
14
Morgan Stanley
New York
$60K +$434 +58 +0.7%
Goldman Sachs
15
Goldman Sachs
New York
$48K +$82 +11 +0.2%
Creative Planning
16
Creative Planning
Kansas
$42K – – –
Cambridge Investment Research Advisors
17
Cambridge Investment Research Advisors
Iowa
$42K +$2.02K +270 +5%
HighTower Advisors
18
HighTower Advisors
Illinois
$29K -$23.7K -3,170 -44%
State Street
19
State Street
Massachusetts
$27K – – –
SWP
20
Stratos Wealth Partners
Ohio
$18K – – –
GC
21
Guggenheim Capital
Illinois
$18K +$112 +15 +0.6%
UBS Group
22
UBS Group
Switzerland
$17K -$33.1K -4,427 -65%
SW
23
SVB Wealth
Massachusetts
$17K – – –
Tudor Investment Corp
24
Tudor Investment Corp
Connecticut
$17K – – –
GWM
25
Greenwich Wealth Management
Connecticut
$15K -$6.98K -933 -31%
1
2 3

NAVB Hedge Fund Activity: Q1 2018 in Review

54 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2018, worth a combined $4.75M — down 3.7% from $4.93M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new NAVB positions and 3 closed out — a net gain of 1 holder — while 11 added to existing stakes and 13 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $23.3K. The largest seller was Sowell Financial Services, cutting an estimated $76K.

  • 54 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $4.75M of Navidea Biopharmaceuticals Inc. stock for Q1 2018, down 3.7% quarter-over-quarter.
  • 4 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2018 and 3 closed out, a net change of +1 holder.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2018 was Citadel Advisors, an estimated $23.3K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2018 was Sowell Financial Services, an estimated $76K sold.

Based on aggregated 13F filings for Q1 2018.